WeiningerWorks

Neuraminidase Case Study
Neuraminidase active site mapping using wwavePDB and twwistPDB arrow Neuramindase Case Study1 arrow Neuramindase Case Study2 arrow Neuramindase Case Study3 arrow Neuramindase Case Study4 arrow Neuramindase Case Study5 arrow Neuramindase Case Study6 arrow Neuramindase Case Study7 arrow Neuramindase Case Study8 arrow Neuramindase Case Study9 arrow Neuramindase Case Study10 arrow Neuramindase Case Study11 arrow Neuramindase Case Study12 arrow Neuramindase Case Study13 arrow Neuramindase Case Study14 arrow Neuramindase Case Study15

Mouse over the small images above to change larger image and associated description. (Alternatively, read static PDF.)

In this example, one set of WWaveMarkers was derived from wwavePDB analysis of six closely related neuraminidase structures. 3B7E2 was used as the reference structure onto which the other neuraminidase structures were mapped. A seventh structure, 4FVK6, and an eight structure, 4GEZ7, were of a highly divergent N10 neuraminidase from a bat virus. The first set of WWaveMarkers could not be used with the N10 neuraminidase structures due to mutations of N10 neuraminidase residues whose atoms were in the first set of WWaveMarkers. A second set of WWaveMarkers was derived from the wwavePDB analysis of 4FVK6 and 4GEZ7 relative to the reference structure 3B7E2. The structures analyzed in this study were:

1W1X1 neuraminidase subtype N6 in complex with sialic acid
2HTU3 neuraminidase subtype N8 in complex with peramivir (BioCryst)
2HU43 neuraminidase subtype N1 in complex with oseltamivir (Roche)
3B7E2 neuraminidase subtype N1 (1918 a/brevig) in complex with zanamivir (GSK)
2QWA4 neuraminidase subtype N9 with R292K mutation
1A145 neuraminidase subtype N9 with engineered VH and VL antibody domains bound
4FVK6 neuraminidase subtype N10 with divergent sequence
4GEZ7 neuraminidase subtype N10 with divergent sequence

The first set of neuraminidase WWaveMarkers (atom serial # - residue - residue #) were:

  PDB    NH    O    OH 
3B7E  #269    ARG   118   #744    TRP   178   #2468  TYR   406 
1W1X  #3308  ARG 1124   #3779  TRP 1185   #5497  TYR 1412 
2HTU  #279    ARG   118   #753    TRP   180   #2489  TYR   411 
2HU4  #270    ARG   118   #741    TRP   178   #2458  TYR   406 
2QWA  #269    ARG   118   #744    TRP   178   #2531  TYR   406 
1A14  #296    ARG   118   #774    TRP   178   #2533  TYR   406 

The distances (D, in Angstroms) between the first set of neuraminidase WWaveMarkers are:

PDB D( O ↔ NH ) D( O ↔ OH ) D( NH ↔ OH )
3B7E  744 ↔ 269:   9.706   744 ↔ 2468:   8.834   269 ↔ 2468:   4.321 
1W1X  3779 ↔ 3308:   9.961   3779 ↔ 5497:   8.654   3308 ↔ 5497:   4.267 
2HTU  753 ↔ 279:   9.987   753 ↔ 2489:   8.617   279 ↔ 2489:   4.552 
2HU4  741 ↔ 270:   9.732   741 ↔ 2458:   8.735   270 ↔ 2458:   4.329 
2QWA  744 ↔ 269:   9.919   744 ↔ 2531:   8.464   269 ↔ 2531:   4.261 
1A14  774 ↔ 269: 10.558   774 ↔ 2533:   8.587   269 ↔ 2533:   4.773 

The first set of neuraminidase WWaveMarkers are shown in the image above color coded according to element ( N  O ).

The second set of neuraminidase WWaveMarkers (atom serial # - residue - residue #) were:

  PDB    O    O    O 
3B7E  #262  ARG  118   #1089  ARG  224   #1487  GLU  276 
4FVK  #3169  ARG  118   #3974  ARG  224   #4385  GLU  276 
4GEZ  #8859  ARG  111   #9664  ARG  215   #10075  GLU  267 

The distances (D, in Angstroms) between the second set of neuraminidase WWaveMarkers are:

PDB D( O ↔ O ) D( O ↔ O ) D( O ↔ O )
3B7E  262 ↔ 1089:   14.730   262 ↔ 1487:   15.001   1089 ↔ 1487:   8.332 
4FVK  3169 ↔ 3974:   14.197   3169 ↔ 4385:   15.190   3974 ↔ 4385:   8.793 
4GEZ  8859 ↔ 9664:   14.178   8859 ↔ 10075:   15.353   9664 ↔ 10075:   8.924 


Neuraminidase binding compounds

(The highlighted colors of the following SMILES match structures on the neuraminidase binding compounds page)

sialic acid (also named “SIA”)
IUPAC Name: (2R,4S,5R,6R)-5-acetamido-2,4-dihydroxy-6
               -[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid

SMILES: CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)O[C@](C(=O)O)(O)C[C@@H]1O

MUNANA (also named “MUS”)
IUPAC Name: (2S,4S,5R,6R)-5-acetamido-4-hydroxy-2
               -(4-methyl-2-oxochromen-7-yl)oxy-6
               -[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid

SMILES: CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)O[C@H](C(=O)O)
               (Oc2cc3oc(=O)cc(C)c3cc2)C[C@@H]1O

KDN
IUPAC Name: (2S,4S,5R,6R)-2,4,5-trihydroxy-6-[(1R,2R)
               -1,2,3-trihydroxypropyl]oxane-2-carboxylic acid

SMILES: O[C@H]1[C@H]([C@H](O)[C@H](O)CO)O[C@](O)(C(=O)O)C[C@@H]1O

zanamivir (also named “ZMR”)
IUPAC Name: (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)
               -2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H
               -pyran-6-carboxylic acid

SMILES: CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(C(=O)O)=C[C@@H]1N=C(N)N

oseltamivir (also named “G39”)
IUPAC Name: (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene
               -1-carboxylic acid

SMILES: CC(=O)N[C@H]1[C@H](OC(CC)CC)C=C(C(=O)O)C[C@@H]1N

peramivir (also named “BCZ”)
IUPAC Name: (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]
               -4-(diaminomethylideneamino)
               -2-hydroxycyclopentane-1-carboxylic acid

SMILES: CC(=O)NN[C@@H](C(CC)CC)[C@@H]1[C@H](O)[C@@H](C(=O)O)C[C@H]1N=C(N)N


1 1W1X (neuraminidase complexed with sialic acid).
   Rudino-Pinera, E.; Tunnah, P.; Crennell, S.J.; Webster, R.G.; Laver, W.G.; Garman, E.F.;
   “The Crystal Structure Of Type A Influenza Virus Neuraminidase Of The N6 Subtype
     Reveals The Existence Of Two Separate Neu5ac Binding Sites”
   To Be Published/REVDAT 2H24-FEB-09 1W1X

2 Protein Data Bank ID: 3B7E (neuraminidase complexed with zanamivir).
   Xu, X.; Zhu, X.; Dwek, R.A.; Stevens, J.; Wilson, I.A;
   “Structural characterization of the 1918 influenza virus H1N1 neuraminidase.”
   J. Virology (2008) 82: 10493-10501

3 2HTU (neuraminidase complexed with peramivir)
   2HU4 (neuraminidase complexed with oseltamivir).
   Russell, R.J.; Haire, L.F.; Stevens, D.J.; Collins, P.J.; Lin, Y.P.; Blackburn, G.M.;
   Hay, A.J.; Gamblin, S.J.; Skehel, J.J.;
   “The structure of H5N1 avian influenza neuraminidase suggests new opportunities
     for drug design.”
   Nature (2006) 443: 45-49

4 2QWA (R292K mutant neuraminidase).
   Varghese, J.N.; Smith, P.W.; Sollis, S.L.; Blick, T.J.; Sahasrabudhe, A.;
   McKimm-Breschkin, J.L.; Colman, P.M.;
   “Drug design against a shifting target: a structural basis for resistance to
     inhibitors in a variant of influenza virus neuraminidase.”
   Structure (1998) 6: 735-746

5 1A14 (neuraminidase complexed with VH and CL antibody domains).
   Malby, R.L.; McCoy, A.J.; Kortt, A.A.; Hudson, P.J.; Colman, P.M.;
   “Three-dimensional structures of single-chain Fv-neuraminidase complexes.”
   J.Mol.Biol. (1998) 279: 901-910

6 4FVK (divergent neuraminidase isolated from bats).
   Li, Q.; Sun, X.M,; Li, Z.X.; Liu, Y.; Vavricka, C.J.; Qi, J.X.; Gao G.F.;
   “Structural and functional characterization of neuraminidase-like molecule n10
     derived from bat influenza a virus.”
   Proc.Natl.Acad.Sci.USA (2012) 109: 18897-18902

7 4GEZ (divergent neuraminidase isolated from bats).
   Zhu, X.; Yang, H.; Guo, Z.; Yu, W.; Carney, P.J.; Li, Y.; Chen, L.M.; Paulson, J.C.;
   Donis, R.O.; Tong, S.; Stevens, J.; Wilson, I.A.;
   “Crystal structures of two subtype N10 neuraminidase-like proteins from bat
     influenza A viruses reveal a diverged putative active site.
   Proc.Natl.Acad.Sci.USA (2012) 109: 18903-18908

Back to top

sitemap